Table 3A.
Outcome analysis: In‐H mortality
| Variable | 0 (N = 249) | 1 (N = 29) | Average marginal effect (AME) | p | Lower | Upper |
|---|---|---|---|---|---|---|
| CAC | 48% | 68% | 0.0725 | .027 | 0.0079 | 0.1371 |
| Age (years) | 51.4/61.9/74.1 | 67.7/74.8/83.7 | 0.0056 | <.001 | 0.0031 | 0.0082 |
| Male sex | 66% | 79% | −0.0571 | .078 | −0.1205 | 0.0063 |
| Hypertension | 46% | 83% | 0.1364 | <.001 | 0.0653 | 0.2076 |
| Diabetes | 23% | 21% | −0.0142 | .717 | −0.0912 | 0.0627 |
| Smoking | 15% | 24% | 0.0643 | .24 | −0.043 | 0.1715 |
| Obesity | 19% | 23% | 0.0198 | .6792 | −0.074 | 0.1136 |
| Dyslipidemia | 27% | 52% | 0.1111 | .013 | 0.0233 | 0.1989 |
| WBC | 3.785/5.130/7.030 | 3.330/4.270/7.860 | −0.0003 | .942 | −0.009 | 0.0083 |
| Creatinine (mg/dl) | 0.7/0.840/1.100 | 0.7/1.0/1.2 | −0.0038 | .548 | −0.0162 | 0.0086 |
| CRP admission (mg/L) | 20/59/96 | 60/98/130 | 0.0006 | .008 | 0.0002 | 0.0011 |
| Procalcitonin | 0.40/0.08/0.20 | 0.09/0.20/0.40 | 0.0178 | .308 | −0.0164 | 0.052 |
| Saturation O2% | 93/96/97 | 88/91/94 | −0.0093 | .003 | −0.0154 | −0.0032 |
| HScTnI admission | 3.00/7.00/18.00 | 14.00/29.00/107.75 | 0 | .981 | −0.0003 | 0.0003 |
| Lung consolidation | 63% | 82% | 0.0805 | .015 | 0.0155 | 0.1455 |
| GGO | 81% | 89% | 0.0527 | .091 | −0.0083 | 0.1138 |
| Bilateral involvement | 86% | 93% | 0.0575 | .243 | −0.0391 | 0.154 |
| Antibiotic use | 94% | 100% | 0.1038 | <.001 | 0.0691 | 0.1386 |
| Antiviral use | 38% | 22% | −0.0607 | .096 | −0.1322 | 0.0109 |
| Hydroxychloroquine | 31% | 37% | 0.0235 | .549 | −0.0535 | 0.1006 |
| Corticosteroids | 56% | 78% | 0.0799 | .011 | 0.0183 | 0.1415 |
| Tocilizumab | 6% | 4% | −0.0383 | .618 | −0.1886 | 0.112 |
| Plasma | 16% | 11% | −0.0341 | .374 | −0.1094 | 0.0411 |
| Days in ICU | 6/11/20 | 12/20/35 | 0.0082 | .0123 | 0.0018 | 0.0146 |
| d‐dimer >1000 | 8% | 34% | 0.2663 | .004 | 0.0847 | 0.4480 |
| HScTnI‐peak 34–200 | 12% | 31% | 0.2245 | .006 | 0.0658 | 0.3833 |
| HScTnI‐peak >200 | 5% | 62% | 0.6046 | <.001 | 0.4039 | 0.8053 |
| Previous CAD | 9% | 24% | 0.1606 | .0491 | 0.0007 | 0.3205 |
| Chronic kidney disease | 9% | 8% | 0.05415 | .3761 | −0.06575 | 0.174 |
| Peripheral vasculopathy | 9% | 8% | −0.01054 | .8781 | −0.1452 | 0.1241 |
| Pulmonary hypertension | 1% | 0% | ||||
| Chronic broncopneumopathy | 4% | 12% | 0.1448 | .1766 | −0.06523 | 0.3549 |
| Previous malignancy | 9% | 16% | 0.07429 | .3949 | −0.09685 | 0.2454 |
| Active malignancy | 9% | 16% | 0.06778 | .3147 | −0.06436 | 0.1999 |
| Multivariate analysis: AME, p (p‐value), and lower and upper bound of the 95% confidence interval | ||||||
| Variable | AME | p | Lower | Upper |
|---|---|---|---|---|
| Antibiotic treatment | 0.1052 | <.001 | 0.0537 | 0.1568 |
| Peak HScTnI 34–200 | 0.2398 | .010 | 0.0582 | 0.4214 |
| Peak HScTnI >200 | 0.5792 | <.001 | 0.4354 | 0.7231 |
Note: Data are percentages for categorical variables and I quartile/median/III quartile for continuous variables. The table also reports the results of the univariate models, as AME, p (p‐value), and lower and upper bound of the 95% confidence interval
Abbreviations: CAC, coronary artery calcium; CAD, coronary artery disease; CRP, C‐reactive protein; GGO, ground‐glass opacification; HScTnI, high‐sensitivity cardiac troponin I; ICU, intensive care unit; in H, in hospital; WBC, white blood count.